GlassScriptPhysician profile
Dustin Albert
NPI 1689968463
$1,353.29
in general payments reported to CMS, 2019-2025
21 companies · $877 in 2025
The $877 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $476 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $326.95 | 2024-2025 | |
| Madrigal Pharmaceuticals | $262.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $105.37 | 2024-2025 | Sutab, Suflave |
| Ardelyx, INC. | $73.07 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $64.88 | 2025 | Eohilia, Gattex |
| Genzyme Corporation | $64.54 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $62.80 | 2024-2025 | Vowst |
| Mallinckrodt Hospital Products INC. | $54.50 | 2025 | Terlivaz |
| Novo Nordisk INC | $48.92 | 2025 | Wegovy |
| Janssen Biotech, INC. | $48.61 | 2025 | Tremfya, Simponi, Stelara |
| Phathom Pharmaceuticals, INC. | $39.32 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $29.15 | 2024 | Injectafer |
| Fresenius Kabi USA, LLC | $24.44 | 2025 | Adalimumab-Aacf |
| Celltrion USA INC. | $22.23 | 2024 | Vegzelma |
| Gilead Sciences, INC. | $20.06 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.77 | 2025 | Uplizna |
| Ferring Pharmaceuticals INC. | $19.35 | 2024 | Rebyota |
| Lilly USA, LLC | $17.98 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $16.40 | 2025 | |
| Shield Therapeutics INC | $16.28 | 2024 | |
| Pfizer INC. | $15.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.